First Western Trust Bank Sells 2,595 Shares of Stryker Co. (NYSE:SYK)

First Western Trust Bank reduced its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 0.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,497,138 shares of the medical technology company's stock after selling 2,595 shares during the period. Stryker accounts for 56.8% of First Western Trust Bank's portfolio, making the stock its biggest holding. First Western Trust Bank owned 0.92% of Stryker worth $1,263,376,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Stryker by 78.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company's stock worth $45,260,000 after purchasing an additional 58,673 shares in the last quarter. OFI Invest Asset Management raised its holdings in shares of Stryker by 3,210.9% during the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company's stock worth $1,062,000 after acquiring an additional 3,243 shares in the last quarter. Tidal Investments LLC raised its holdings in shares of Stryker by 14.2% during the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company's stock worth $4,853,000 after acquiring an additional 1,681 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Stryker by 2.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company's stock worth $210,289,000 after acquiring an additional 16,504 shares in the last quarter. Finally, Fiera Capital Corp raised its holdings in shares of Stryker by 42.1% during the 2nd quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company's stock worth $5,687,000 after acquiring an additional 4,948 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 0.4 %

NYSE:SYK traded up $1.37 on Monday, reaching $391.45. The company's stock had a trading volume of 1,286,398 shares, compared to its average volume of 1,266,773. Stryker Co. has a 12-month low of $285.79 and a 12-month high of $398.20. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $364.07 and a 200 day moving average price of $347.54. The firm has a market cap of $149.23 billion, a price-to-earnings ratio of 41.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same period in the previous year, the firm posted $2.46 earnings per share. The company's revenue was up 11.9% on a year-over-year basis. On average, equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Insider Activity

In related news, insider Viju Menon sold 600 shares of the business's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company's stock, valued at $3,219,495. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,381 shares of company stock valued at $24,825,275. 5.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SYK shares. Citigroup upped their price objective on Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Truist Financial increased their price target on Stryker from $370.00 to $380.00 and gave the stock a "hold" rating in a research report on Wednesday, October 30th. BTIG Research upped their price objective on Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Piper Sandler restated an "overweight" rating and set a $420.00 price objective (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, Stifel Nicolaus decreased their price objective on Stryker from $375.00 to $365.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.